This company has been marked as potentially delisted and may not be actively trading. RXi Pharmaceuticals (RXII) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock RXII vs. NNVC, TAOX, IBIO, GRAY, OBSV, AEON, MTNB, AEZS, NRBO, and VAXXShould you be buying RXi Pharmaceuticals stock or one of its competitors? The main competitors of RXi Pharmaceuticals include NanoViricides (NNVC), Synaptogenix (TAOX), iBio (IBIO), Graybug Vision (GRAY), ObsEva (OBSV), AEON Biopharma (AEON), Matinas Biopharma (MTNB), Aeterna Zentaris (AEZS), NeuroBo Pharmaceuticals (NRBO), and Vaxxinity (VAXX). RXi Pharmaceuticals vs. Its Competitors NanoViricides Synaptogenix iBio Graybug Vision ObsEva AEON Biopharma Matinas Biopharma Aeterna Zentaris NeuroBo Pharmaceuticals Vaxxinity NanoViricides (NYSE:NNVC) and RXi Pharmaceuticals (NASDAQ:RXII) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, risk and dividends. Is NNVC or RXII more profitable? NanoViricides has a net margin of 0.00% compared to RXi Pharmaceuticals' net margin of -4,990.20%. NanoViricides' return on equity of -87.90% beat RXi Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets NanoViricidesN/A -87.90% -78.69% RXi Pharmaceuticals -4,990.20%-412.15%-179.54% Which has more volatility & risk, NNVC or RXII? NanoViricides has a beta of 0.96, indicating that its stock price is 4% less volatile than the S&P 500. Comparatively, RXi Pharmaceuticals has a beta of 2.07, indicating that its stock price is 107% more volatile than the S&P 500. Does the media favor NNVC or RXII? In the previous week, NanoViricides had 1 more articles in the media than RXi Pharmaceuticals. MarketBeat recorded 1 mentions for NanoViricides and 0 mentions for RXi Pharmaceuticals. NanoViricides' average media sentiment score of 0.50 beat RXi Pharmaceuticals' score of 0.00 indicating that NanoViricides is being referred to more favorably in the media. Company Overall Sentiment NanoViricides Positive RXi Pharmaceuticals Neutral Do institutionals & insiders have more ownership in NNVC or RXII? 10.3% of NanoViricides shares are owned by institutional investors. Comparatively, 9.6% of RXi Pharmaceuticals shares are owned by institutional investors. 4.6% of NanoViricides shares are owned by company insiders. Comparatively, 1.0% of RXi Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Which has stronger earnings and valuation, NNVC or RXII? NanoViricides has higher earnings, but lower revenue than RXi Pharmaceuticals. NanoViricides is trading at a lower price-to-earnings ratio than RXi Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNanoViricidesN/AN/A-$8.29M-$0.70-2.06RXi Pharmaceuticals$10K915.42-$12.45M-$4.20-0.50 SummaryNanoViricides beats RXi Pharmaceuticals on 9 of the 12 factors compared between the two stocks. Get RXi Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RXII and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RXII and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RXII vs. The Competition Export to ExcelMetricRXi PharmaceuticalsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.15M$832.60M$5.76B$9.58BDividend YieldN/A4.84%4.41%4.10%P/E Ratio-0.501.1731.1026.04Price / Sales915.4226.34433.45102.77Price / CashN/A19.5637.7358.48Price / Book2.716.659.536.61Net Income-$12.45M-$4.94M$3.26B$265.56M RXi Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RXIIRXi PharmaceuticalsN/A$2.09+1.0%N/A-32.8%$9.15M$10K-0.50N/AGap UpNNVCNanoViricides0.7424 of 5 stars$1.54flatN/A-21.7%$24.75MN/A-2.1420TAOXSynaptogenixN/A$8.34+12.9%N/AN/A$10.27MN/A-0.834Earnings ReportGap UpIBIOiBio1.8894 of 5 stars$0.57-2.3%$5.00+772.4%-60.3%$9.47M$375K0.00100News CoverageGap DownGRAYGraybug VisionN/A$2.76+0.7%N/A-33.3%$8.64MN/A-1.6027Gap UpHigh Trading VolumeOBSVObsEvaN/AN/AN/AN/A$7.94MN/A0.0050Gap DownAEONAEON Biopharma2.9126 of 5 stars$0.69+5.0%$360.00+52,134.5%-98.9%$7.79MN/A3.835Gap DownMTNBMatinas Biopharma0.7058 of 5 stars$1.48-7.5%N/AN/A$7.53MN/A-0.3130AEZSAeterna ZentarisN/A$3.58-0.4%N/A-55.3%$6.42M$2.37M-0.2420NRBONeuroBo PharmaceuticalsN/A$0.64+1.3%N/A-82.5%$5.50MN/A0.0010VAXXVaxxinityN/A$0.04+42,900.0%N/A-70.0%$5.45MN/A-0.1090Gap Up Related Companies and Tools Related Companies NNVC Alternatives TAOX Alternatives IBIO Alternatives GRAY Alternatives OBSV Alternatives AEON Alternatives MTNB Alternatives AEZS Alternatives NRBO Alternatives VAXX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RXII) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RXi Pharmaceuticals Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share RXi Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access